Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreements, Nyxol License Agreement (Details)

v3.23.1
License and Collaboration Agreements, Nyxol License Agreement (Details)
1 Months Ended 3 Months Ended
Nov. 30, 2022
USD ($)
Mar. 31, 2023
USD ($)
Performanceobligation
Mar. 31, 2022
USD ($)
Nov. 06, 2022
USD ($)
Collaboration and License Agreement [Abstract]        
Revenue recognized   $ 1,749,000 $ 0  
Reconciliation of Closing Balance of Contract Asset [Abstract]        
Beginning Balance   3,552,000    
Revenue recognized   1,749,000 $ 0  
Ending Balance   $ 2,467,000    
Nyxol License Agreement [Member]        
Collaboration and License Agreement [Abstract]        
Non-refundable cash payment received $ 35,000,000      
Maximum amount of payments receivable for development, regulatory and commercial milestones       $ 130,000,000
First potential payments to be received       $ 10,000,000
Maximum percentage of tiered royalties receivable   20.00%    
Number of distinct performance obligations | Performanceobligation   2    
Aggregate transaction price to be recognized   $ 40,000,000    
Period of non-cancellation window agreement   120 days    
Non-cancellation period of constrained   120 days    
Revenue recognized   $ 1,749,000    
Reconciliation of Closing Balance of Contract Asset [Abstract]        
Beginning Balance   3,552,000    
Revenue recognized   1,749,000    
Ending Balance   2,467,000    
Nyxol License Agreement [Member] | License Transfer Fee [Member]        
Collaboration and License Agreement [Abstract]        
Aggregate transaction price to be recognized   35,000,000    
Estimated standalone selling price for license agreement   287,800,000    
Transaction price allocation of ESSP obligations   39,300,000    
Reconciliation of Closing Balance of Contract Asset [Abstract]        
Reclassification to accounts receivable related to costs billed under the Nyxol License Agreement   (2,834,000)    
Nyxol License Agreement [Member] | Research and Development Services [Member]        
Collaboration and License Agreement [Abstract]        
Aggregate transaction price to be recognized   5,000,000    
Estimated standalone selling price for license agreement   5,000,000    
Transaction price allocation of ESSP obligations   700,000    
Nyxol License Agreement [Member] | Sales Milestones [Member]        
Collaboration and License Agreement [Abstract]        
Revenue recognized   0    
Reconciliation of Closing Balance of Contract Asset [Abstract]        
Revenue recognized   $ 0